Program
Factor X
Its studies are mostly in Blood Coagulation Disorders, led by Kedrion.
Furthest: phase 3, since Apr 14, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kedrion | 10 open or running | phase 3since Apr 14, 2025 | Apr 14, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2025First study: phase 3 study in Factor X DeficiencyFirst studyNCT06963216
TargetBeta
F10 →read by rule
“Coagulation factor X exogenous protein”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| apixabanrule | Bristol-Myers Squibb | phase 4 | 44 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06963216Factor X Deficiency | 3 | Withdrawn | Jun 10, 2026 | 0 |
How it is read
Names in the registry
- “Coagadex(R)”, 1 entry
Conditions, from the studies’ own filings
- Blood Coagulation Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.